Updated guidelines from the European League Against Rheumatism (EULAR), based on new evidence and a review of the literature from 2016 to 2018, address recommendations on the use of disease-modifying antirheumatic drugs and glucocorticoids to treat patients with rheumatoid arthritis (RA). Included is guidance on mono- and combination therapies, treatment strategies, and tapering treatment.
Since the European League Against Rheumatism’s (EULAR) initial recommendations in 2010 for how to manage rheumatoid arthritis (RA) with disease-modifying antirheumatic drugs (DMARDs), progress in the field necessitated 2 updates in 2013 and 2016. A third update was just released in the Annals of Rheumatic Diseases.
With clinical remission the main goal of RA treatment, using DMARDs enables symptom relief; improves physical function, quality of life, and social/work capacity; and inhibits structural damage to cartilage and bone.
This most recent update comprises 5 principles and 12 recommendations on the use of DMARDs—conventional synthetic (cs; methotrexate, leflunomide, sulfasalazine), biological (b; tumour necrosis factor [TNF] inhibitors [adalimumab, certolizumab pegol, etanercept, golimumab, infliximab], abatacept, rituximab, tocilizumab, sarilumab), biosimilar, and targeted synthetic (ts; Janus kinase inhibitors tofacitinib, baricitinib, filgotinib, upadacitinib)—and glucocorticoids to treat patients with RA. Included is guidance on mono- and combination therapies, treatment strategies, and tapering treatment. Altogether, this update considers patient benefits, safety, preferences, and costs related to RA treatment.
The 5 principles build on the previous updates, but they are not based on “specific scientific evidence.” Instead, they are overarching and address treating patients with RA:
The 12 recommendations also incorporate information from the previous updates. However, unlike the principles, they should be followed in this order:
These updated guidelines come on the heels of several new drug approvals in Europe after the 2016 update, and several of the principles and recommendations remain unchanged. However, the authors expect them to be revised again, and soon, so that patients can continue to receive optimal treatment from their treating rheumatologists and other stakeholders remain updated on progress in the field.
“We have reached a steady state of the evidence base for patients with established RA, although still some needs remain unmet, including the need to cure the disease. With the current rate of evidence development, we expect an update of the recommendations to be necessary in about 3-4 years,” they concluded.
Reference
Smolen JS, Landewé, RB, Bijlsma JWJ, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update [published online January 22, 2020]. Ann Rheum Dis. doi: 10.1136/annrheumdis-2019-216655.
Data Show Promise for Adalimumab Biosimilars to Deliver on Safety, Cost Savings
May 16th 2024Two posters from the Academy of Managed Care Pharmacy’s annual meeting provided hope that despite low uptake so far, adalimumab biosimilars can deliver on the promise of comparable safety and efficacy with the originator in multiple disease states, as well as cost savings.
Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars
March 17th 2024On this episode of Not So Different, Ha Kung Wong, JD, an intellectual patent attorney and partner at Venable LLP, details the confusing landscape that is the US patent system and how it can be improved to help companies overcome barriers to biosimilar competition.
Review: Product Attributes Relevant to Injection-Site Pain, Adalimumab Treatment
May 4th 2024A review article summarizes the product attributes of reference and biosimilar adalimumab products, such as formulation with or without citrate, delivery volume, and needle gauge, relevant to patients’ experience of injection-site pain.
Biosimilars Rheumatology Roundup for February 2024—Podcast Edition
March 3rd 2024On this episode of Not So Different, The Center for Biosimilars® revisited all the major rheumatology biosimilar news from February 2024, including the FDA approval of the 10th adalimumab biosimilar, the promise for an oral delivery system for ustekinumab, and the impact of adalimumab products on COVID-19 antibodies.
Eye on Pharma: EU Ustekinumab Approval; New Golimumab Data; Evernorth Adds Humira Biosimilar
April 29th 2024The European Union gained a new ustekinumab biosimilar; Alvotech released positive results from a clinical trial evaluating a golimumab biosimilar and the reference products (Simponi and Simponi Aria), and Evernorth announced that it is set to cover an adalimumab biosimilar at zero cost to patients.